Cowen & Co. Upgrades PerkinElmer to Outperform, Lowers Price Target to $164
Cowen & Co. analyst Max Masucci upgrades PerkinElmer (NYSE:PKI) from Market Perform to Outperform and lowers the price target from $192 to $164.
Barclays Upgrades PerkinElmer to Equal-Weight, Raises Price Target to $145
Barclays analyst Luke Sergott upgrades PerkinElmer (NYSE:PKI) from Underweight to Equal-Weight and raises the price target from $130 to $145.
PerkinElmer Launches Ready-to-use Adeno-associated Virus Vectors Detection Kits To Support Researchers Working On Gene Therapies
PerkinElmer, Inc., (NYSE:PKI), a global leader committed to innovating for a healthier world, today launched ready-to-use Adeno-associated Virus Vectors (AAV) Detection Kits to support researchers working on
Credit Suisse Maintains Neutral on PerkinElmer, Lowers Price Target to $160
Credit Suisse analyst Dan Leonard maintains PerkinElmer (NYSE:PKI) with a Neutral and lowers the price target from $175 to $160.
PerkinElmer Q3 EPS Adj. $1.51 Beats $1.45 Estimate, Sales (including AES) $1.03B Beat $1.01B Estimate
PerkinElmer (NYSE:PKI) reported quarterly earnings of $1.51 per share which beat the analyst consensus estimate of $1.45 by 4.14 percent. This is a 34.63 percent decrease over earnings of $2.31 per share from the same
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
PerkinElmer Anticipated Organic Revenue Growth, Non-COVID Organic Revenue Growth And Adj. EPS For Q3 To Exceed Prior Guidance
The Company also announced that it anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share for the third quarter ended October 2, 2022 to exceed itsThe Company also announced that it anticipates organic revenue growth, non-COVID organic revenue growth, and adjusted earnings per share for the third quarter ended October 2, 2022 to
FDA To Review Smaller Number Of Emergency Use Requests For COVID-19 Tests
The FDA said it will now review only a small number of emergency use authorization (EUA) requests for COVID-19 diagnostic…
